(CTNM) Contineum Therapeutics - Overview
Stock: PIPE-791, PIPE-307, CTX-343
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 78.4% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.92 |
| Alpha | 48.17 |
| Character TTM | |
|---|---|
| Beta | 0.262 |
| Beta Downside | 1.496 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.37% |
| CAGR/Max DD | -0.03 |
Description: CTNM Contineum Therapeutics January 17, 2026
Contineum Therapeutics, Inc. (NASDAQ: CTNM) is a clinical-stage biopharma based in San Diego that focuses on small-molecule therapeutics for high-unmet-need areas in neuroscience, inflammation, and immunology across the United States.
The lead program, PIPE-791, is a brain-penetrant LPA1 receptor antagonist being evaluated for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (MS), and chronic pain. Additional assets include PIPE-307, a selective M1-muscarinic receptor inhibitor in Phase 2 for depression and relapse-remitting MS, and CTX-343, a peripherally restricted LPA1 antagonist intended for peripheral indications. The company, formerly Pipeline Therapeutics, rebranded to Contineum in November 2023.
Key sector drivers that could affect CTNM’s valuation are the growing $6 billion US IPF market, a 5-year CAGR of ~8 % for neuro-inflammation therapeutics, and the historically low 8 % success rate for Phase 2-to-Approval transitions in CNS drugs-metrics that underscore both upside potential and execution risk. As of the latest 10-Q, the company reported $45 million in cash and equivalents, giving it roughly 12 months of runway at current burn rates, while recent financing rounds have diluted existing shareholders but provided capital to advance PIPE-791 into pivotal trials.
For a deeper quantitative assessment, see the ValueRay profile on CTNM.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -59.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -11.94 > 1.0 |
| NWC/Revenue: 73.8k% < 20% (prev 418.7%; Δ 73.4k% < -1%) |
| CFO/TA -0.27 > 3% & CFO -52.5m > Net Income -59.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 29.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.1m) vs 12m ago 9.27% < -2% |
| Gross Margin: -16.12% > 18% (prev 1.00%; Δ -1711 % > 0.5%) |
| Asset Turnover: 0.12% > 50% (prev 23.14%; Δ -23.03% > 0%) |
| Interest Coverage Ratio: -29.01 > 6 (EBITDA TTM -61.2m / Interest Expense TTM -2.12m) |
Altman Z'' -15.00
| A: 0.94 (Total Current Assets 184.9m - Total Current Liabilities 6.36m) / Total Assets 190.8m |
| B: -0.85 (Retained Earnings -162.2m / Total Assets 190.8m) |
| C: -0.30 (EBIT TTM -61.5m / Avg Total Assets 203.4m) |
| D: -15.60 (Book Value of Equity -161.9m / Total Liabilities 10.4m) |
| Altman-Z'' Score: -15.05 = D |
What is the price of CTNM shares?
Over the past week, the price has changed by +7.95%, over one month by +52.10%, over three months by +42.82% and over the past year by +62.33%.
Is CTNM a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CTNM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.3 | 33.7% |
| Analysts Target Price | 20.3 | 33.7% |
| ValueRay Target Price | 18.1 | 19% |
CTNM Fundamental Data Overview February 03, 2026
P/B = 2.9552
Revenue TTM = 242.0k USD
EBIT TTM = -61.5m USD
EBITDA TTM = -61.2m USD
Long Term Debt = 5.49m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.48m USD (from shortTermDebt, last quarter)
Debt = 5.49m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -37.1m USD (from netDebt column, last quarter)
Enterprise Value = 344.0m USD (520.9m + Debt 5.49m - CCE 182.4m)
Interest Coverage Ratio = -29.01 (Ebit TTM -61.5m / Interest Expense TTM -2.12m)
EV/FCF = -6.51x (Enterprise Value 344.0m / FCF TTM -52.8m)
FCF Yield = -15.36% (FCF TTM -52.8m / Enterprise Value 344.0m)
FCF Margin = -21.8k% (FCF TTM -52.8m / Revenue TTM 242.0k)
Net Margin = -24.5k% (Net Income TTM -59.4m / Revenue TTM 242.0k)
Gross Margin = -16.12% ((Revenue TTM 242.0k - Cost of Revenue TTM 281.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.80 (Enterprise Value 344.0m / Total Assets 190.8m)
Interest Expense / Debt = -38.59% (Interest Expense -2.12m / Debt 5.49m)
Taxrate = 21.0% (US default 21%)
NOPAT = -48.6m (EBIT -61.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 29.07 (Total Current Assets 184.9m / Total Current Liabilities 6.36m)
Debt / Equity = 0.03 (Debt 5.49m / totalStockholderEquity, last quarter 180.5m)
Debt / EBITDA = 0.61 (negative EBITDA) (Net Debt -37.1m / EBITDA -61.2m)
Debt / FCF = 0.70 (negative FCF - burning cash) (Net Debt -37.1m / FCF TTM -52.8m)
Total Stockholder Equity = 183.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.19% (Net Income -59.4m / Total Assets 190.8m)
RoE = -32.33% (Net Income TTM -59.4m / Total Stockholder Equity 183.7m)
RoCE = -32.51% (EBIT -61.5m / Capital Employed (Equity 183.7m + L.T.Debt 5.49m))
RoIC = -26.45% (negative operating profit) (NOPAT -48.6m / Invested Capital 183.7m)
WACC = 6.81% (E(520.9m)/V(526.4m) * Re(6.88%) + (debt cost/tax rate unavailable))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 5.77%
Fair Price DCF = unknown (Cash Flow -52.8m)
EPS Correlation: 68.69 | EPS CAGR: 29.03% | SUE: 0.59 | # QB: 0
Revenue Correlation: -29.53 | Revenue CAGR: 0.0% | SUE: -1.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.56 | Chg30d=+0.077 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.20 | Chg30d=+0.110 | Revisions Net=+2 | Growth EPS=-7.1% | Growth Revenue=-62.3%